The proprietary ENDOSKELETON® interbody devices are designed to promote bony ongrowth, optimize intervertebral stability, allow for increased bone graft material, and permit excellent visualization on postoperative CT and MRI scans.
Proprietary textured macro surface on the superior and inferior surfaces provide strong initial bone purchase. Micro and cellular textures on all surfaces support multi-axial new bone growth.
Enable majority of the devices to be placed on the apophyseal ring, the strongest portion of the vertebral endplate, to preserve endplate integrity and reduce the risk of implant subsidence.
Devices utilize less material and feature extremely large windows for excellent postoperative radiographic visualization and fusion evaluation, as well as increased bone graft volume. Furthermore, side windows allow for additional bone growth in the axial plane, unlike traditional interbody devices that only allow for cephalad/caudal bone growth.
Simplified surgical technique. The ENDOSKELETON® line of devices is supported by simple, intuitive instrumentation for easy and consistent implantation. The devices are available in a variety of sizes to accommodate various patient anatomies.
- ALIF cage option for cases that require additional fixation without the need for supplemental posterior instrumentation
- Features three integrated grit-blasted screws for immediate mechanical stability; allow for up to 10° of medial/lateral or anterior/posterior angular variation
- Unique texture of both cage and screw surfaces helps secure device in place upon implantation and helps to prevent screw back-out
- Available in thirty-six sizes for increased surgeon choice and improved anatomical fit
The Endoskeleton® TAS device is indicated for use in skeletally mature patients with Degenerative Disc Disease (DDD) at one or two contiguous levels from L2-S1. DDD is defined as discogenic back pain with degeneration of the disc confirmed by patient history and radiographic studies. These DDD patients may also have up to Grade 1 spondylolisthesis or retrolisthesis at the involved level(s). Patients should have received 6 months of non-operative treatment prior to surgical treatment with the device. The Endoskeleton® TAS is indicated to be used with autograft bone. The device is a standalone system intended to be used with the bone screws provided and requires no additional supplementary fixation. This implant may be covered by one or more patents and pending patent applications.